FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. (FENC) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 14% planned / 86% discretionary
Largest single sale: $7.5M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Raykov Rosty | Other | Sell 10b5-1 | 10,000 | $12.11 | $121.1K | 124,411 −7.4% of holding | |
| Sayad Pierre Sargis | Chief Medical Officer | Sell | 12,000 | $12.18 | $146.2K | 9,519 −55.8% of holding | |
| Andrade Robert | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 75,000 | $11.78 | $883.5K | 217,675 −25.6% of holding | |
| Raykov Rosty | Other | Sell 10b5-1 | 10,000 | $9.58 | $95.8K | 131,633 −7.1% of holding | |
| Raykov Rosty | Other | Sell 10b5-1 | 9,599 | $10.41 | $99.9K | 138,855 −6.5% of holding | |
| Raykov Rosty | Director | Sell 10b5-1 | 9,747 | $9.62 | $93.8K | 130,079 −7% of holding | |
| RALLIS CHRIS A | Director | Sell | 8,346 | $7.04 | $58.8K | 63,077 −11.7% of holding | |
| Raykov Rosty | Director | Sell 10b5-1 | 10,781 | $6.47 | $69.8K | 121,451 −8.2% of holding | |
| Raykov Rosty | Director | Sell 10b5-1 | 10,946 | $6.31 | $69.1K | 113,856 −8.8% of holding | |
| Raykov Rosty | Director | Sell | 10,079 | $8.36 | $84.3K | 103,996 −8.8% of holding | |
| Raykov Rosty | Director | Sell | 10,349 | $7.76 | $80.3K | 98,477 −9.5% of holding | |
| Raykov Rosty | Director | Sell | 10,312 | $7.60 | $78.4K | 88,020 −10.5% of holding | |
| Sell | 1,000,000 | $7.50 | $7.5M | 2,744,741 −26.7% of holding | |||
| Raykov Rosty | Director | Sell 10b5-1 | 10,000 | $7.54 | $75.4K | 77,526 −11.4% of holding | |
| Sell | 19,341 | $8.79 | $170.0K | 3,744,741 −0.5% of holding | |||
| Sell | 85,918 | $8.79 | $755.2K | 3,764,082 −2.2% of holding | |||
| Sell | 160,100 | $8.00 | $1.3M | 3,850,000 −4% of holding | |||
| Raykov Rosty | Director | Sell 10b5-1 | 10,000 | $8.10 | $81.0K | 82,318 −10.8% of holding | |
| RALLIS CHRIS A | Director | Sell | 1,775 | $9.24 | $16.4K | 57,079 −3% of holding | |
| Sell | 20,609 | $9.35 | $192.6K | 4,010,100 −0.5% of holding | |||
| Sell | 19,605 | $9.47 | $185.7K | 4,030,709 −0.5% of holding | |||
| Sell | 26,900 | $9.59 | $257.9K | 4,050,314 −0.7% of holding | |||
| Raykov Rosty | Director | Sell 10b5-1 | 10,000 | $9.78 | $97.8K | 82,501 −10.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.